The potential impact of male circumcision on HIV in sub-Saharan Africa PLoS Medicine Brian G.

The potential impact of male circumcision on HIV in sub-Saharan Africa PLoS Medicine Brian G. Williams, James O. Lloyd – Smith, Eleanor Gouws, Catherine Hankins, Wayne M. John Hargrove, Isabelle de Zoysa, Christopher Dye, Bertran Auvert here see Abstract and article online.

More than three million people living in sub-Saharan Africa could be saved alone, they say.

The work of financing and WMG was Jols grant from NIH – NIDA R01 support – DA10135 and James S. McDonnell Foundation 21st Century Science initiative grant. The funders had. No role in study design, data collection and analysis, decision to publish , or preparation of the manuscript.. Through the used Male circumcision million future HIV infections Cut circumcision reduces HIV infection risk by 60 percent in heterosexual men could reduce the number of HIV infections in sub-Saharan Africa more than six million in the next two decades, says an international research team led by Catherine Hankins, Chief Scientific Adviser, led the United Nations program on HIV / AIDS .Nick James, a professor of Clinical Oncology, Institute for Cancer Studies, Birmingham wrote, and lead investigator for the EPOC survey: Men with advanced prostate are by with hormone therapies While this therapy to provide great advantages most men develop resistance. Against them. Currently the only therapy approved to metastases patients to survive to improve the survival men with HRPC being docetaxel chemotherapy .. Suggests Wide – Ranging ZD4054 Phase III development the program for the treatment of prostate cancer.

The OS results were as follows:intent-to-treat population ZD4054 ZD4054 15mg 10mg Placebo number of the patients 98,107,107 number of the mortality 34 33 51 medially overall survival 23.3 hazard ratio as compared to placebo from 0.55 to 80 % CI 0.73 – The results of randomized, double-blind, placebo-controlled Phase II EPOC Study of ZD4054 – has a specific endothelin A receptor antagonist is – were delivered at the 14th the European Congress of Clinical Oncology .

Patients to 17.3 ZD4054 15 mg once daily seen a 35 per cent reduction in risk of the death (HR 0.65, 80 per cent Cl 0, re translating into improved median OS from 23.5 months with a ZD4054 15 mg of once per day compared to with 17.3 months of the placebo arm in both.